Novo Nordisk faces fierce competition in China’s diabetes drug market

Novo Nordisk faces fierce competition in China’s diabetes drug market

Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

Novo Nordisk A/S (NYSE:NVO) Sees Strong Trading Volume – Time to Buy?

Novo Nordisk A/S (NYSE:NVO – Get Free Report) saw unusually-high trading volume on Monday . Approximately 9,587,590 shares traded hands during trading, an increase of 41% from the previous session’s volume of 6,813,352 shares.The stock last traded at $71.51 and had previously closed at $71.50. Analyst Ratings Changes Several equities research analysts have issued reports […]

Biocon Targets 'Diabesity': Biocon's Kiran Mazumdar Shaw Sees Massive Opportunity in GLP-1 Drugs for Diabetes and Obesity

Biocon Eyes Dominant Role in 'Diabesity' Market Through GLP-1 Drug FocusBiopharmaceutical major Biocon is strategically positioning itself to become a leading global player in the burgeoning market for "diabesity" treatments—simultaneously addressing diabetes and obesity—by capitalizing on the significant potential of innovative GLP-1 (Glucagon-like peptide-1) drugs. Kiran Mazumdar Shaw, Biocon's Executive Chairperson, recently articulated this …